Hyloris Pharmaceuticals SA Logo

Hyloris Pharmaceuticals SA

HYL | BR

Overview

Corporate Details

ISIN(s):
BE0974363955
LEI:
875500LZIWS7QEQE0I73
Country:
Belgium
Address:
Boulevard de Patience et Beaujonc 3, 4000 Liège
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Hyloris Pharmaceuticals SA is a specialty biopharma company focused on innovating, reinventing, and optimizing existing medications to address unmet medical needs. The company's core strategy involves reformulating and repurposing established drugs by leveraging abbreviated regulatory pathways, such as the U.S. FDA's 505(b)(2) framework. This approach aims to reduce development timelines, costs, and risks. Hyloris has built a broad, patented portfolio of value-added medicines designed to offer significant improvements for patients, healthcare professionals, and payors. Its commercialized products include Sotalol IV for atrial fibrillation and Maxigesic® IV, a non-opioid post-operative pain treatment. The company also develops and markets high-barrier generic products.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Hyloris Pharmaceuticals SA. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-22 07:00
M&A Activity
Press Release Hyloris Signs XTRAZA Licensing Agreement with HUONS.pdf
English 206.8 KB
2025-08-22 07:00
M&A Activity
PR Hyloris Signs XTRAZA Licensing Agreement with Huons FR.pdf
French 221.6 KB
2025-07-17 07:00
Regulatory News Service
Press Release_ Atomoxetine Clinical Trial_EN.pdf
English 221.8 KB
2025-07-17 07:00
Regulatory News Service
Press Release_Atomoxetine Clinical Trial_FR.pdf
French 248.2 KB
2025-07-17 07:00
Regulatory News Service
Press Release_ Atomoxetine Clinical Trial_EN.pdf
English 221.8 KB
2025-07-17 07:00
Regulatory News Service
Press Release_Atomoxetine Clinical Trial_FR.pdf
French 248.2 KB
2025-06-23 07:00
M&A Activity
PR Hyloris_Kuvatris Therapeutics_Partnership EN.pdf
English 251.4 KB
2025-06-23 07:00
Share Issue/Capital Change
PR Hyloris_Kuvatris Therapeutics_Partenariat FR.pdf
French 289.9 KB
2025-06-10 20:00
Post-Annual General Meeting Information
PR AGM 2025 - Hyloris EN.pdf
English 140.7 KB
2025-06-10 20:00
Post-Annual General Meeting Information
PR AGM 2025 - Hyloris FR.pdf
French 173.5 KB
2025-06-10 20:00
Post-Annual General Meeting Information
Minutes Ordinary General Shareholders Meeting_ENG_10 June 2025.pdf
English 3.9 MB
2025-06-10 20:00
Post-Annual General Meeting Information
Minutes Ordinary General Shareholders Meeting_FR_10 June 2025.pdf
French 3.9 MB
2025-05-22 07:00
M&A Activity
PR XTRAZA with AFT_En.pdf
English 118.3 KB
2025-05-22 07:00
Regulatory News Service
PR XTRAZA with AFT_FR.pdf
French 160.5 KB
2025-05-13 07:00
M&A Activity
PR Valacyclovir AFT and QliniQ_En.pdf
English 144.5 KB

Automate Your Workflow. Get a real-time feed of all Hyloris Pharmaceuticals SA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Hyloris Pharmaceuticals SA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-06-13 Aichhorn Dietmar Executive member Buy 12,500 144,375.00 EUR
2023-06-13 Vandebroek Jean-Luc Executive member Buy 6,000 69,300.00 EUR
2022-04-14 Van der Elst Koenraad Executive member Sell 3,312 56,466.40 EUR
2022-03-22 Aichhorn Dietmar Executive member Buy 20,000 347,000.00 EUR
2022-03-22 Vandebroek Jean-Luc Board Buy 3,000 52,050.00 EUR

Peer Companies

Company Country Ticker View
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France ALDVI
AegirBio AB Logo
Makes saliva-based diagnostics accessible for at-home & pro health & drug monitoring.
Sweden AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France AELIS
AGRONOMICS LIMITED Logo Isle of Man ANIC
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark ALK